Article Text

Download PDFPDF

1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer
  1. Heleen Roose1,
  2. Kristina Rekstyte-Matiene1,
  3. Sarah Stevens2,
  4. Kusum Gupta2,
  5. Sandra Chang2,
  6. Cheng Liu2,
  7. Vladimir Serebryany2,
  8. Lillian Adame2,
  9. Kha Le2,
  10. Antitsa Stoycheva2,
  11. Lawrence M Blatt2,
  12. Leonid Beigelman2,
  13. Sushmita Chanda2,
  14. David B Smith2,
  15. Julian A Symons2,
  16. Andreas Jekle2 and
  17. Tongfei Wu1
  1. 1Aligos Belgium BV, Leuven, Vlaams-Brabant, Belgium
  2. 2Aligos Therapeutics, Inc., South San Francisco, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background PD-1/PD-L1 antibody-based therapies have demonstrated success in the treatment of liver cancers. Most systemic immune-related adverse events (irAEs) associated with PD-1/PD-L1 antibodies are mild to moderate, but severe irAEs can be life threatening, due to the long half-lives of antibodies. Here, we report the discovery of an orally bioavailable PD-L1 small molecule inhibitor, ALG-094103, which preferentially partitions into the liver and may thereby mitigate extra-hepatic irAEs.

Methods The biochemical interaction of PD-1/PD-L1 and PD-L1 dimerization was assessed by AlphaLISA®. Cellular activity was measured using a co-culture assay of PD-1 expressing Jurkat NFAT luciferase T-cells with PD-L1 expressing CHO cells. Pharmacokinetic (PK) and tissue distribution studies were performed in C57BL/6 mice and PK in Wistar Han rats. In vivo PD-L1 target occupancy was assessed at 6 hours following a single dose in the humanized-PD-L1 MC38 subcutaneous mouse model.

Results ALG-094103 inhibits the PD-1/PD-L1 axis with similar potency to PD-1/PD-L1 antibodies. In addition, ALG-094103 has in vitro potency similar to a non-liver targeted PD-L1 small molecule inhibitor, INCB086550, which demonstrated clinical response in a phase I study. The oral bioavailability of ALG-094193 in rats following a single dose at 15 mg/kg dosing was 40%. ALG-094103 demonstrated significantly higher liver concentrations vs. other tested tissues (liver/lung ratio of 17) in mice at 12 hours after a single oral dose. In the in vivo PD-L1 target occupancy model, oral dosing of ALG-094103 at 50 mg/kg demonstrated higher PD-L1 target occupancy than oral dosing of INCB086550 at 150 mg/kg and IV dosing of durvalumab at 5 mg/kg.

Conclusions We have discovered a novel liver-targeted and orally bioavailable PD-L1 small molecule inhibitor, ALG-094103, with comparable in vitro potency to INCB086550. The properties of ALG-094103 will be further evaluated as a potential candidate for drug development.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.